← back to search

Aly‐Khan A. Lalani

Juravinski Cancer Centre ·
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, and Cancer Genomics and Diagnostics.
h-index
26
citations
2,835
works
196
NIH funding
primary concept
Medicine
email

Recent publications

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Journal of Clinical Oncology 2024cited by 148position: middledoi
Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
European Urology 2024cited by 25position: middledoi
Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).
Journal of Clinical Oncology 2024cited by 10position: middledoi
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma
European Urology 2023cited by 65position: middledoi
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Clinical Cancer Research 2021cited by 34position: middledoi
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma
European Journal of Cancer 2020cited by 68position: middledoi
Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma
European Urology Oncology 2019cited by 96position: firstdoi
Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study
European Urology Oncology 2019cited by 48position: middledoi
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
Journal for ImmunoTherapy of Cancer 2018cited by 261position: firstdoi
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
Cancer Immunology Research 2018cited by 136position: middledoi
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
Cancer Immunology Research 2018cited by 62position: middledoi
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
British Journal of Cancer 2018cited by 44position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Toni K. Choueiri · Harvard University9 papers (2018–2024)Bradley A. McGregor · Harvard University6 papers (2018–2021)Rana R. McKay · The Barbara Ann Karmanos Cancer Institute5 papers (2018–2024)Dylan J. Martini · Massachusetts General Hospital4 papers (2018–2020)John A. Steinharter · University of Vermont4 papers (2018–2020)Lauren C. Harshman · Dana-Farber/Harvard Cancer Center4 papers (2018–2020)Sumanta K. Pal · City of Hope3 papers (2018–2024)Wanling Xie · Wuhan University3 papers (2018–2020)Lori Wood · Nova Scotia Health Authority3 papers (2023–2024)Daniel Y.C. Heng · Eindhoven Cancer Registry3 papers (2023–2024)Dominick Bossé · University of Ottawa3 papers (2018–2019)Naveen S. Basappa · Alberta Health Services3 papers (2023–2024)Benoit Beuselinck · Universitair Ziekenhuis Leuven2 papers (2024–2024)Xiao X. Wei · Dana-Farber Cancer Institute2 papers (2019–2020)Ajjai Alva · University of Colorado Anschutz Medical Campus2 papers (2018–2023)Mehmet Asım Bilen · Emory Healthcare2 papers (2020–2021)Guru Sonpavde · AdventHealth Orlando2 papers (2018–2019) · 2 papers (2023–2024)Bernadett Szabados · University College London Hospitals NHS Foundation Trust2 papers (2023–2024)Luís Meza · Yale University2 papers (2023–2024)